Skip to content

Safety Study of Continuous Positive Airway Pressure Via a Nasal Mask

Effect of Continuous Positive Airway Pressure Ventilation Through Nasal Mask on Upper Airway Patency During Induction of Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01524614
Enrollment
80
Registered
2012-02-02
Start date
2011-10-31
Completion date
2012-05-31
Last updated
2017-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Airway Obstruction

Keywords

continuous positive airway pressure, nasal mask, upper airway obstruction

Brief summary

Upper airway obstruction (UAO) is common complication during induction of general anesthesia. The mechanism of UAO during anesthesia has not been well understood. Posterior displacement of soft palate are believed to be the primary contributing factors. The mechanism of UAO during anesthesia share many similarities with obstructive sleep apnea (OSA). Since nasal continuous positive airway pressure (nCPAP) can maintain the airway patent in patients with OSA, the investigators hypothesize that nCPAP during induction of anesthesia will reduce the incidence and severity of UAO.

Interventions

PROCEDUREnasal mask

nasal mask use instead of face mask

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Patients,between 18-65 years of age meeting ASA physical status classification I-II requiring general anesthesia for elective surgery who are able to breathe through both their nose and mouth while awake.

Exclusion criteria

1. Patients with major cardiovascular disease, respiratory disease, cerebral vascular disease or American Society of Anesthesiologists physical status class III or greater. 2. Abnormal vital signs on the day of admission for surgery \[heart rate (HR, \> 100 bpm or \< 40 bpm), blood pressure (BP, \> 180/100 mmHg or \< 90/60 mmHg), room air transcutaneous oxyhemoglobin saturation (SPO2) \< 96%\] that are not correctable with his or her routine medication or commonly used pre-operative medication. 3. Unable to open mouth (\< 2.5 cm) or unable to breathe through their mouth or nose. 4. Subjects with a beard, an abnormal facial structure or other factors precluding obtaining a viable face mask fit without air leak. Also, subjects having claustrophobia that can not tolerate the mask. 5. Any person with an anticipated difficult airway. This will include subjects who require or may require either a fiberoptic intubation or intubation while awake and subjects with known OSA or body mass index (BMI) greater than 35 km/m2. 6. Gastric-esophageal reflex or a full stomach. 7. The subject has remained in bed for more than 24 hours. 8. Neurological symptoms associated with neck extension, a neurological deficit from a previous stroke or spinal cord injury, a recent stroke or transient ischemic attack (TIA) within 2 weeks. 9. Pregnant women and women less than one month post-partum. Ruling out pregnancy will be conducted by careful history and physical examination as performed routinely prior to surgery. If the history is believed to be unreliable, the patient will be excluded unless a pregnancy test is performed and the result of the test is negative. 10. Emergency cases and subjects who have not adhered to the ASA NPO (Nil Per Os) guidelines.

Design outcomes

Primary

MeasureTime frameDescription
expired tidal volumeAverage of one minute after anesthesia inductionEstimated time from induction of anesthesia (drugs given for anesthesia induction) to apnea is one minute.

Secondary

MeasureTime frameDescription
volume of CO2Average of one minute after anesthesia inductionEstimated time from induction of anesthesia (drugs given for anesthesia induction) to apnea is one minute.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026